IBDEI1UA ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,32393,1,3,0)
 ;;=3^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,32393,1,4,0)
 ;;=4^E87.5
 ;;^UTILITY(U,$J,358.3,32393,2)
 ;;=^60041
 ;;^UTILITY(U,$J,358.3,32394,0)
 ;;=E89.2^^182^1984^46
 ;;^UTILITY(U,$J,358.3,32394,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32394,1,3,0)
 ;;=3^PostProcedural Hypoparathyroidism
 ;;^UTILITY(U,$J,358.3,32394,1,4,0)
 ;;=4^E89.2
 ;;^UTILITY(U,$J,358.3,32394,2)
 ;;=^5003037
 ;;^UTILITY(U,$J,358.3,32395,0)
 ;;=E89.6^^182^1984^45
 ;;^UTILITY(U,$J,358.3,32395,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32395,1,3,0)
 ;;=3^PostProcedural Adrenocortical Hypofunction
 ;;^UTILITY(U,$J,358.3,32395,1,4,0)
 ;;=4^E89.6
 ;;^UTILITY(U,$J,358.3,32395,2)
 ;;=^5003042
 ;;^UTILITY(U,$J,358.3,32396,0)
 ;;=L68.0^^182^1984^24
 ;;^UTILITY(U,$J,358.3,32396,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32396,1,3,0)
 ;;=3^Hirsutism
 ;;^UTILITY(U,$J,358.3,32396,1,4,0)
 ;;=4^L68.0
 ;;^UTILITY(U,$J,358.3,32396,2)
 ;;=^5009262
 ;;^UTILITY(U,$J,358.3,32397,0)
 ;;=M80.00XA^^182^1984^2
 ;;^UTILITY(U,$J,358.3,32397,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32397,1,3,0)
 ;;=3^Age-Related Osteoporosis w/ Fx,Unspec Site,Init Encntr
 ;;^UTILITY(U,$J,358.3,32397,1,4,0)
 ;;=4^M80.00XA
 ;;^UTILITY(U,$J,358.3,32397,2)
 ;;=^5013363
 ;;^UTILITY(U,$J,358.3,32398,0)
 ;;=M81.0^^182^1984^3
 ;;^UTILITY(U,$J,358.3,32398,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32398,1,3,0)
 ;;=3^Age-Related Osteoporosis w/o Fx
 ;;^UTILITY(U,$J,358.3,32398,1,4,0)
 ;;=4^M81.0
 ;;^UTILITY(U,$J,358.3,32398,2)
 ;;=^5013555
 ;;^UTILITY(U,$J,358.3,32399,0)
 ;;=M85.80^^182^1984^43
 ;;^UTILITY(U,$J,358.3,32399,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32399,1,3,0)
 ;;=3^Osteopenia,Unspec
 ;;^UTILITY(U,$J,358.3,32399,1,4,0)
 ;;=4^M85.80
 ;;^UTILITY(U,$J,358.3,32399,2)
 ;;=^5014473
 ;;^UTILITY(U,$J,358.3,32400,0)
 ;;=N62.^^182^1984^23
 ;;^UTILITY(U,$J,358.3,32400,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32400,1,3,0)
 ;;=3^Gynecomastia
 ;;^UTILITY(U,$J,358.3,32400,1,4,0)
 ;;=4^N62.
 ;;^UTILITY(U,$J,358.3,32400,2)
 ;;=^5015790
 ;;^UTILITY(U,$J,358.3,32401,0)
 ;;=E10.43^^182^1984^6
 ;;^UTILITY(U,$J,358.3,32401,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32401,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Autonomic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,32401,1,4,0)
 ;;=4^E10.43
 ;;^UTILITY(U,$J,358.3,32401,2)
 ;;=^5002607
 ;;^UTILITY(U,$J,358.3,32402,0)
 ;;=E10.59^^182^1984^4
 ;;^UTILITY(U,$J,358.3,32402,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32402,1,3,0)
 ;;=3^DM Type 1 w/ Circulatory Complications
 ;;^UTILITY(U,$J,358.3,32402,1,4,0)
 ;;=4^E10.59
 ;;^UTILITY(U,$J,358.3,32402,2)
 ;;=^5002612
 ;;^UTILITY(U,$J,358.3,32403,0)
 ;;=E10.618^^182^1984^5
 ;;^UTILITY(U,$J,358.3,32403,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32403,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Arthropathy
 ;;^UTILITY(U,$J,358.3,32403,1,4,0)
 ;;=4^E10.618
 ;;^UTILITY(U,$J,358.3,32403,2)
 ;;=^5002614
 ;;^UTILITY(U,$J,358.3,32404,0)
 ;;=E10.621^^182^1984^7
 ;;^UTILITY(U,$J,358.3,32404,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32404,1,3,0)
 ;;=3^DM Type 1 w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,32404,1,4,0)
 ;;=4^E10.621
 ;;^UTILITY(U,$J,358.3,32404,2)
 ;;=^5002616
 ;;^UTILITY(U,$J,358.3,32405,0)
 ;;=E10.622^^182^1984^10
 ;;^UTILITY(U,$J,358.3,32405,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32405,1,3,0)
 ;;=3^DM Type 1 w/ Skin Ulcer
 ;;^UTILITY(U,$J,358.3,32405,1,4,0)
 ;;=4^E10.622
 ;;^UTILITY(U,$J,358.3,32405,2)
 ;;=^5002617
 ;;^UTILITY(U,$J,358.3,32406,0)
 ;;=E10.65^^182^1984^8
 ;;^UTILITY(U,$J,358.3,32406,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32406,1,3,0)
 ;;=3^DM Type 1 w/ Hyperglycermia
 ;;
 ;;$END ROU IBDEI1UA
